EverNov

EverNov Therapeutics is a clinical-stage biopharmaceutical company headquartered in Beijing, China, specializing in the discovery of next-generation small molecule drugs for cancer and autoimmune disorders. Founded by industry veterans with extensive experience in global pharmaceutical R&D, the company utilizes a sophisticated structure-based drug design (SBDD) platform to tackle difficult-to-drug targets. Its primary focus lies in modulating the RAS/MAPK signaling pathway, with its lead candidate, EN001, currently in Phase 1 clinical trials as a selective SHP2 inhibitor. EverNov's strategy combines internal innovation with a focus on precision oncology to develop therapies that overcome resistance in advanced malignancies. The company is backed by prominent life science investors, including Lilly Asia Ventures and Morningside Venture Capital.